AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sanofi

WASHINGTON (AP) — U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.

New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis'

RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.

FDA Approves Antibody For RSV After Challenging 2022 Season

The U.S. Food and Drug Administration on Monday approved a Sanofi SNY, +0.28% and AstraZeneca PLC AZN, -0.60% respiratory syncytial virus vaccine for newborns and infants. The RSV vaccine, Beyfortus, was approved for prevention of RSV lower respiratory tract disease in babies entering their first RSV vaccine as well as children up to two years old who remain vulnerable to severe RSV, the FDA said in a release.

FDA approves Sanofi and AstraZeneca infant RSV vaccine

While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.

FDA Approves First RSV Drug to Protect All Infants

Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition. Nirsevimab is administered either before or during an infant's first RSV season.

FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV

U.S. Food and Drug Administration said on Monday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.

US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies

CVS Health

Medtronic

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), AstraZeneca (NASDAQ:AZN)

LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against AstraZeneca PLC and Encourages Investors with Losses to Contact the Firm

Moderna

Pfizer

Over the past three months, some of the world's biggest pharmaceutical companies, including Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and AstraZeneca (NASDAQ: AZN), have seen double-digit declines in their stock prices.

Pfizer, AstraZeneca, and Moderna lost $67 billion in market value since April

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

Following AstraZeneca PLC's (LSE:AZN) update on its new cancer drug, datopotamab deruxtecan (Dato-DXd), several brokers have weighed in, including Deutsche Bank downgrading its stance and UBS saying the press release was "quite vague". Shares in the largest company on the FTSE 100 dropped almost 8% at the start of the week, erasing £14bn of value from the company's market cap and sending the shares to a four-month low below 10,400p.

AstraZeneca rebounds as analysts mull 'hard to read' cancer drug update

AstraZeneca PLC (NASDAQ:AZN) is gapping lower today, after the biopharmaceutical name's lung cancer drug disappointed investors in a late-stage trial.

Biopharma Stock Gaps Lower After Trial Disappoints

AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.

AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment

AstraZeneca's AZN, +1.02% AZN, -5.43% shares slumped 6% in premarket trade. The U.K. drugmaker said its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.

AstraZeneca shares slump after Phase 3 lung cancer drug study

Tesla

Tesla stock TSLA, +1.66% soared 6% in premarket trade after the electric vehicle maker reported a record number of deliveries in the second quarter.

Tesla shares rally on delivery numbers, AstraZeneca stock slumps on drug trial, and other stocks on the move

Shares in pharmaceutical giant AstraZeneca PLC (LSE:AZN) fell 4.4% in early trading, erasing £7.3bn from the company's market value. The drop comes amid investor concerns over the results of a high-profile study of its new cancer drug, datopotamab deruxtecan (Dato-DXd).

AstraZeneca sees £7bn wiped from its value as lung cancer results fall short of 'best-case scenario'

British drugmaker AstraZeneca said on Monday its anti-body drug for lung cancer had met two of its main goals in a late-stage trial.

AstraZeneca reports positive results in late-stage trial of lung cancer therapy

British drugmaker AstraZeneca on Wednesday announced it would invest $400 million to plant over 200 million trees by 2030 as part of its strategy for reducing carbon emissions in line with the Paris Agreement.

AstraZeneca to spend $400 mln to plant 200 mln trees, cut carbon footprint

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Expansion of AZ Forest for climate action and human health.

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Dividend-paying pharma stocks frequently deliver market-beating returns on capital. AstraZeneca stock, for instance, has consistently trounced the broader markets over the past 10 years.

Is AstraZeneca a Top Stock to Buy Right Now?

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

AstraZeneca plc (LON: AZN) is considering spinning off its business in China, the Financial Times reported on Monday. Listing in Shanghai or Hong Kong also possible The pharmaceutical behemoth could restructure its operations in the said region and list them as a separate legal entity in Shanghai or Hong Kong, the daily business newspaper added.

AstraZeneca may soon spin off its business in China

UK's largest stock-market-listed firm weighs up Hong Kong or Shanghai listing to shield it from geopolitical tensions

AstraZeneca considers spinning off its China business

AstraZeneca PLC (LSE:AZN), the UK's largest listed company, is considering carving out its China business and listing it separately in Hong Kong, as a potential shield against escalating geopolitical tensions, according to the Financial Times. The Anglo-Swedish pharmaceutical giant is among a rising number of multinational corporations mulling over such strategic restructuring in response to growing friction between China, the US, and its allies, the paper said.

News for AstraZeneca Stock (AZN)